Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

ALSTX vs. SBIO: which is better?

Bottom line

ALSTX vs SBIO: the short answer

ALSTX (ALPS/Stadion Core ETF Portfolio) and SBIO (ALPS Medical Breakthroughs ETF) are both mutual funds.

Updated Nov 19, 2026

ALSTX vs SBIO side by side

ALSTXSBIO
TypeMutual fundETF
Fund familyAlps VariableAlps
CategoryLarge BlendHealth Care Sector
Expense ratio—0.5%
Annual cost per $10k—$50
10-yr cost on $10k (prospectus)—$628
Max front load—None
12b-1 fee——
1-yr return—+54.2%
5-yr return (annualized)—+0.7%
10-yr return (annualized)—+5.7%
Best quarter—+33.9%
Worst quarter—−30.8%
Net assets (fund)—$161.8M
Number of holdings—89
Portfolio turnover—58%
Returns as of—Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Holdings overlap

ALSTX and SBIO share none of their top holdings.

ALSTX top 10

    SBIO top 10

    1. Alkermes Plc — 4.48%
    2. Kymera Therapeutics Inc — 4.23%
    3. Celcuity Inc — 3.92%
    4. Mirum Pharmaceuticals Inc — 3.90%
    5. Spyre Therapeutics Inc — 3.68%
    6. Cg Oncology Inc — 3.35%
    7. Apogee Therapeutics Inc — 2.93%
    8. Xenon Pharmaceuticals Inc — 2.90%
    9. Travere Therapeutics Inc — 2.77%
    10. Dianthus Therapeutics Inc — 2.64%

    FAQ

    What is the difference between ALSTX and SBIO?
    ALSTX (ALPS/Stadion Core ETF Portfolio) and SBIO (ALPS Medical Breakthroughs ETF) are both mutual funds.
    Should I own both ALSTX and SBIO?
    Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

    Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.